Articles tagged with Ovarian Cancer
Researchers found that biomarker levels began to rise 3 years before clinical diagnosis, but became substantially elevated only a year prior. While not accurate enough for early intervention, these markers are associated with modest increases in ovarian cancer risk.
A genetic signature associated with poor patient outcomes could lead to improved therapies for ovarian cancer. The study found that MAGP2, a previously unknown cancer gene, was overexpressed in tumors of patients who died more quickly.
Research from the American Journal of Pathology reveals that glycosaminoglycans contribute to skeletal abnormalities in patients with lysosomal storage diseases. Additionally, αvβ3-integrin expression improves ovarian cancer patient prognosis, while CpG DNA may be a therapeutic candidate for Alzheimer's disease treatment.
A new study finds that women with a deleterious BRCA gene mutation are diagnosed with breast cancer six years earlier than their relatives who also had the disease and/or ovarian cancer. The findings could impact how women at highest risk for breast cancer are counseled and screened in the future.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
The Fox Chase-Penn Ovarian SPORE program will focus on three central concepts in ovarian cancer: epigenetics, predictive biomarkers, and targeted therapeutics. The grant will fund five main research projects and three core facilities to support multidisciplinary research efforts.
Researchers at the University of Gothenburg have developed a new treatment that uses a radioactive substance to seek and destroy tumour cells in ovarian cancer patients. The treatment, which has shown no unwanted side-effects in an initial study, aims to provide a more effective alternative to current treatments.
A new genetic marker associated with ovarian cancer risk was discovered by a research group led by scientists from the University of Hawaii at Manoa. The marker is present among 32% of women and contributes an estimated 0.7% to ovarian cancer risk, particularly for serous carcinoma subtype.
A recent analysis of 1.2 million Swedish hospital cases reveals that heart failure is associated with poor survival rates, more deaths, and premature life-years lost compared to common cancers. Heart failure affects more men and women than most cancer types, particularly in Sweden.
A new study published in the American Cancer Society's journal finds that young women with early-stage ovarian cancer can preserve future fertility by conserving at least one ovary or the uterus. Researchers analyzed data from over 1,800 patients and found those who conserved an ovary had similar survival rates for up to five years.
Researchers developed nanoparticles that selectively delivered diphtheria toxin genes to ovarian cancer cells, slowing tumor growth and increasing lifespan by nearly four weeks. This therapy shows promise as a targeted treatment for advanced ovarian cancer.
A new gene therapy technique using nanoparticles has shown promise in suppressing ovarian tumor growth in mice, offering a potential treatment for late-stage ovarian cancer. The nanoparticles deliver a killer gene that kills cells by disrupting protein production, avoiding toxic side effects common with traditional chemotherapy.
Researchers developed a novel therapeutic delivery system that targets EphA2 protein in ovarian cancer cells, delivering chemotherapy with high specificity and reducing tumor growth by up to 98%. The therapy shows promising results in preclinical models and is expected to enter phase I clinical trials soon.
A novel immunoconjugate targeting EphA2 protein shows substantial antitumor activity in ovarian cancer cell lines and mice. The agent inhibits tumor growth by 85% compared to control, with significant effects on proliferation and apoptosis.
Current diagnostic tests for ovarian cancer are ineffective for early detection, but a new study suggests that with improved testing, tumors can be detected up to 4.3 years before diagnosis and treatment is possible. The window of opportunity for successful treatment is surprisingly long, making reliable early detection crucial.
Researchers developed models to understand the growth and progression of serous ovarian cancer, identifying key properties for a biomarker-based screening test. The study aimed to guide rational design of an early detection strategy, potentially leading to improved outcomes for women diagnosed with this aggressive type of ovarian cancer.
Early-stage ovarian tumors can remain undetectable for years due to their small size, posing a significant challenge in early detection. The study suggests that detecting these microscopic tumors within a four-year window could enable surgeons to remove them before they spread.
A subset of infiltrating monocyte-derived macrophages, expressing interleukin-10, exhibits an anti-inflammatory role in spinal cord injuries. This suggests that these cells may have a beneficial effect on recovery from such injuries.
Researchers at Dartmouth Medical School have developed a Trojan horse nanoparticles to target ovarian cancer, reprogramming protective cells into killers. The approach triggers an inflammatory immune response, directly killing tumor cells and potentially complementing current therapies.
Women taking hormone therapy have a 38% increased risk of ovarian cancer, with risks increasing by 44% for epithelial tumors. The absolute risk is approximately 1 extra ovarian cancer for every 8,300 women taking hormone therapy annually.
Researchers found African Americans have lower survival rates for breast, prostate, and ovarian cancers due to biological factors, not socioeconomic ones. The study of 19,457 patients showed 49% more likelihood of death from early-stage breast cancer among African Americans.
Two studies found significant racial disparities in breast cancer survival rates, with black women having a higher hazard of death compared to white women. The disparity persists even when controlling for treatment factors and socioeconomic status.
Researchers found a singular mutation in the FOXL2 gene that causes granulosa cell tumours, a rare and often untreatable form of ovarian cancer. The discovery provides a specific diagnostic tool and potential treatment pathway for women with this cancer type.
A new study published in Journal of General Internal Medicine found that few women with family histories of hereditary breast or ovarian cancer are discussing genetic testing with their physicians. Most high-risk women are unaware of the available test or have not discussed it with their clinician.
Researchers found genetic variations in miRNA processing genes and binding sites associated with increased ovarian cancer risk and shorter survival times. Variations also indicated likelihood of response to platinum-based chemotherapy, potentially using a single blood sample for prognosis and therapy prediction.
A pre-clinical study found that adding dasatinib to standard chemotherapy increases the effectiveness of treatment in ovarian cancers with high SRC expression. This synergistic effect was absent in low SRC expressing cancers, suggesting targeted therapies like dasatinib may improve response rates.
A new study found that ultrasound and blood test screening for ovarian cancer only catches the disease in its late stages, resulting in unnecessary surgery. The positive predictive value of these tests is remarkably low, leading to many false positives.
A study at Duke University Medical Center suggests that ovarian cancers detected early on may be slower-growing and less likely to spread than more aggressive forms. This finding challenges the idea of screening for ovarian cancer as a means of reducing mortality.
The largest randomised trial of ovarian cancer screening has shown that both the CA125 blood test and transvaginal ultrasound screening strategies are capable of detecting early stage ovarian cancers. The study detected almost half of all cancers in stage I/II, with a significant improvement in specificity for multimodal screening.
The Ovarian Cancer Research Fund (OCRF) and the Gynecologic Cancer Foundation (GCF) have jointly funded a new study on ovarian cancer symptoms, aiming to develop a systematic screening process. Dr. Barbara Goff will lead the three-year study, which seeks to create a symptom index for early detection.
Research finds that increased angiogenesis and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. High microvessel density and VEGF overexpression were linked to significantly poorer survival rates, as well as recurrence and metastasis.
Researchers have discovered a gene expression signature associated with survival in advanced ovarian cancer. The study identified specific genes and pathways that correlate with overall survival, providing potential targets for therapies and personalized treatment strategies.
A study published in the Journal of Clinical Oncology found that leaving the ovaries intact during surgery for early-stage endometrial cancer has no survival benefit compared to removing them. This approach could spare women from surgery-induced early menopause, hot flashes, and increased risk of heart disease and osteoporosis.
A meta-analysis of 10 studies confirms that risk-reducing salpingo-oophorectomy significantly reduces the risk of breast and ovarian cancers in women with BRCA mutations. The procedure is associated with a 51% relative reduction in breast cancer risk and an 79% relative reduction in ovarian cancer risk.
A new study published by the American Cancer Society found that obesity may contribute to the development of ovarian cancer through a hormonal mechanism. Women who were obese had an almost 80% higher risk of ovarian cancer compared to those of normal weight, particularly in women who had never used menopausal hormone therapy.
Researchers at the University of Texas M. D. Anderson Cancer Center discovered that a tumor-suppressing gene called ARHI acts as a switch for autophagy in ovarian cancer cells, allowing dormant cells to survive by avoiding starvation. Blocking this autophagic pathway could provide a novel strategy for eliminating dormant ovarian cancer...
Researchers found that obese and non-obese patients have the same overall survival rate for ovarian cancer if their chemotherapy doses are tailored to their individual body weight. The study, published in Gynecologic Oncology, challenges earlier research suggesting obesity reduces ovarian cancer survival rates.
A study by the University of Texas M. D. Anderson Cancer Center found that women with high levels of Dicer and Drosha proteins had a median survival of 11 years, while those with low levels had only 2.66 years. Low levels of Dicer are also predictive of poor outcomes in lung and breast cancer patients.
Researchers discovered that blocking proteins produced by the MYC oncogene can halt ovarian cancer cell proliferation. Using RNA interference, they silenced c-Myc and L-Myc proteins in lab cultures with amplified MYC, preventing cancer cell growth.
Researchers at University of California, Berkeley discovered that blocking proteins coded by notorious gene MYC can stop ovarian cancer cell proliferation. By using RNA interference and small interfering RNA to silence L-Myc and N-Myc proteins, the scientists were able to shut down growth in non-amplified MYC tumors.
A recent Ontario study found that only 19% of women with invasive ovarian cancer were referred for genetic testing of BRCA1 and BRCA2 genes, highlighting a lack of awareness about the risks and benefits of genetic testing. This omission puts family members at risk as they are unaware of their potential cancer risk.
A phase III, international randomized clinical trial supports a new standard of treatment for women with advanced ovarian cancer, reducing complications and post-operative deaths. The study demonstrates that neoadjuvant chemotherapy followed by interval debulking surgery can be the preferred treatment for patients with very extensive d...
Research suggests ovarian cancer subtypes have distinct biomarker profiles, affecting patient outcomes and treatment strategies. The study analyzed 500 ovarian cancer samples to identify correlations between biomarkers and survival rates, highlighting the need for subtype-specific approaches.
Researchers at Johns Hopkins have discovered how ovarian tumors use fatty substances to suppress the body's immune response, leaving disease unchecked. The team found that fluid secretions from tumors can block activation of natural killer T cells, which are crucial for fighting cancer.
GUMC researchers will present several scientific findings on black women's health, including the importance of colonoscopy utilization and BRCA1/2 genetic testing. Studies reveal predictors of genetic testing among newly diagnosed breast cancer patients, highlighting the need for clinical practice to identify patients at risk.
Research finds that PEA-15 protein forces ovarian cancer cells to eat themselves, leading to increased median survival time. High levels of PEA-15 are linked to improved patient outcomes and may offer a new dimension for targeting ERK in cancer therapy.
A new anti-cancer compound, BI 6727, has shown encouraging anti-tumour activity in a phase I clinical trial. The compound works by inhibiting the action of Polo-like kinase 1, leading to abnormal mitotic spindles and disrupting cell division.
Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth in ovarian cancer. High levels of TEM1 were correlated with decreased survival rates, making it a potential screening tool for early detection.
A new combination therapy of trabectedin and pegylated liposomal doxorubicin shows clinical benefit for women with relapsed ovarian cancer. The treatment offers an alternative to traditional platinum-based regimens, providing a fresh option for those whose cancer recurs after first-line treatment.
A phase III clinical trial led by UC Irvine's Dr. Bradley Monk found trabectedin to be effective in stopping ovarian cancer cell growth, with a median progression-free time of 9.2 months for those treated with the combination therapy. The treatment has hope for improved treatment of this deadly disease.
A phase II trial of the investigational drug pazopanib has shown promising results in treating ovarian cancer. The study found that 31% of patients experienced a significant decrease in CA-125 levels, with a median duration of response of 113 days.
Researchers found overexpression of TG2 in ovarian cancer to be associated with increased tumor cell growth, adhesion, resistance to chemotherapy, and lower overall survival rates. Silencing TG2 using siRNA reversed cancer progression, suggesting the protein as a novel therapeutic approach for late-stage ovarian cancer.
A Swedish study found that more than 40% of widowers were never informed about their wives' incurable cancer or received the news in the last week of her life. The study suggests room for improvement in healthcare provider communication with husbands, particularly those who did not receive information before the wife's death.
Researchers found that ovarian cancer has a distinct scent different from other cancers, which can be detected by trained dogs. Early-stage and low-grade ovarian cancers emit the same scent as advanced tumors.
A new study finds that combining symptom screening with a simple blood test can detect over 80% of women with early-stage ovarian cancer and nearly 95% with late-stage disease. This approach may lead to improved cure rates for those diagnosed at an earlier stage.
Researchers say combined PET/CT scanning can enable doctors to determine if ovarian cancer has spread without surgery, reducing unnecessary surgeries and complications. The technology showed promising results in accurately staging early-stage ovarian cancer patients.
Researchers at University of Oklahoma discovered a chemical compound that prevents cancer in lab tests, successfully stopping normal cells from turning into cancer cells and inhibiting tumor growth. The compound, SHetA2, is being developed by NCI as a cancer prevention drug to be taken daily like a multi-vitamin.
Researchers discovered glypican-3 loss induces overgrowth through Sonic Hedgehog, a growth factor stimulating cancer growth in rare disorder SGBS. This finding opens doors for novel treatments to inhibit overgrowth activity benefiting SGBS patients and GPC3-related cancer patients.
Researchers at Yale University have discovered a new drug compound, NV-128, that can induce the death of ovarian cancer cells resistant to chemotherapy. The compound works by halting the activation of the mTOR protein pathway, which is associated with tumor growth and resistance to conventional therapies.
Researchers have identified and cloned ovarian cancer stem cells, which may be the source of recurrence and resistance to chemotherapy. These stem cells can replicate indefinitely and are highly resistant to conventional treatment.